» Articles » PMID: 33079905

Brief Report: Virologic and Immunologic Outcomes for HIV Patients With Coronavirus Disease 2019

Overview
Date 2020 Oct 20
PMID 33079905
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: To describe the virologic and immunologic outcomes among people living with HIV (PLHIV) coinfected with SARS-CoV-2.

Setting: Wuhan, China.

Methods: Thirty-five coinfected patients were identified by matching the reported cases in National Notifiable Infectious Disease Report system for COVID-19 and HIV in Wuhan by time of April 19, 2020. Questionnaire-based survey and follow-up with blood sample collection were used to obtain characteristics before COVID-19 and after recovery. Nonparametric Mann-Whitney U test, χ2, or Fisher exact test, Mcnemar test, and Wilcoxon test were conducted.

Results: Twenty of the 35 coinfected patients were identified as asymptomatic/mild/moderate COVID-19 (nonsevere group) and 15 were identified as severe/critical (severe group). The severe and nonsevere group had no differences in demographics, HIV baseline status, the intervals between last tests and follow-up tests for CD4+ cell count and HIV-1 viral load (all P > 0.05). Overall, there was a significantly increased number of coinfected patients with HIV-1 viral load ≥20 copies/mL after recovery (P = 0.008). The median viral load increased significantly after recovery in severe group (P = 0.034), whereas no significant change of HIV-1 viral load was observed in the nonsevere group. Limited change of CD4+ cell count was found (all P > 0.05).

Conclusion: The coinfection of SARS-CoV-2 may put PLHIV at greater risk for HIV-1 viral rebound especially for severe/critical COVID-19, whereas it had limited impacts on CD4+ cell count. Whether continuous antiretroviral therapy against HIV infection would have significant impacts on CD4+ cell count among PLHIV coinfected with SARS-CoV-2 needs further research.

Citing Articles

Human Immunodeficiency Virus-1 Drug Resistance Mutations in Iranian Treatment-experienced Individuals.

Bokharaei-Salim F, Khanaliha K, Monavari S, Kiani S, Tavakoli A, Jafari E Curr HIV Res. 2024; 22(1):53-64.

PMID: 38310469 DOI: 10.2174/011570162X273321240105081444.


Effect of SARS-CoV-2 Breakthrough Infection on HIV Reservoirs and T-Cell Immune Recovery in 3-Dose Vaccinated People Living with HIV.

Qu M, Song B, Yang B, Wang Z, Yu M, Zhang Y Viruses. 2023; 15(12).

PMID: 38140668 PMC: 10748120. DOI: 10.3390/v15122427.


Immune response to BNT162b2 SARS-CoV-2 vaccine in patients living with HIV: The COVIH-DAPT study.

Manni S, Ruetsch C, Fabre R, Ticchioni M, Graca D, Pradier C Front Immunol. 2023; 14:1136723.

PMID: 36949938 PMC: 10025349. DOI: 10.3389/fimmu.2023.1136723.


Effects of tuberculosis and/or HIV-1 infection on COVID-19 presentation and immune response in Africa.

du Bruyn E, Stek C, Daroowala R, Said-Hartley Q, Hsiao M, Schafer G Nat Commun. 2023; 14(1):188.

PMID: 36635274 PMC: 9836341. DOI: 10.1038/s41467-022-35689-1.


HIV viral load suppression before and after COVID-19 in Kinshasa and Haut Katanga, Democratic Republic of the Congo.

Shah G, Etheredge G, Smallwood S, Maluantesa L, Waterfield K, Ikhile O South Afr J HIV Med. 2022; 23(1):1421.

PMID: 36353191 PMC: 9634654. DOI: 10.4102/sajhivmed.v23i1.1421.


References
1.
Vizcarra P, Perez-Elias M, Quereda C, Moreno A, Vivancos M, Dronda F . Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. Lancet HIV. 2020; 7(8):e554-e564. PMC: 7255735. DOI: 10.1016/S2352-3018(20)30164-8. View

2.
Gervasoni C, Meraviglia P, Riva A, Giacomelli A, Oreni L, Minisci D . Clinical Features and Outcomes of Patients With Human Immunodeficiency Virus With COVID-19. Clin Infect Dis. 2020; 71(16):2276-2278. PMC: 7239244. DOI: 10.1093/cid/ciaa579. View

3.
Baskaran V, Murray R, Hunter A, Lim W, McKeever T . Effect of tobacco smoking on the risk of developing community acquired pneumonia: A systematic review and meta-analysis. PLoS One. 2019; 14(7):e0220204. PMC: 6638981. DOI: 10.1371/journal.pone.0220204. View

4.
Wang F, Hou H, Luo Y, Tang G, Wu S, Huang M . The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight. 2020; 5(10). PMC: 7259533. DOI: 10.1172/jci.insight.137799. View

5.
Blanco J, Ambrosioni J, Garcia F, Martinez E, Soriano A, Mallolas J . COVID-19 in patients with HIV: clinical case series. Lancet HIV. 2020; 7(5):e314-e316. PMC: 7159872. DOI: 10.1016/S2352-3018(20)30111-9. View